This sequencing study of 17 acquired immunodeficiency syndrome-related lymphomas (9 primary brain, 8 systemic) and 8 human immunodeficiency virus-negative atypical lymphoproliferations expressing large amounts of the latent membrane protein 1 (LMP1) of Epstein-Barr virus was performed to characterize the carboxy terminal NF-KB activation domain of LMPl at the molecular level in an immunocompromised host. In-frame deletions within the NF-KB activation domain were identified in all but 2 primary brain lymphomas, 4 systemic lymphomas, and 4 atypical lymphoproliferations, ie, in 60% of cases. In addition, non silent point mutations (range 1 to 5, mean 3.3) were detected in all cases.
Although all changes occurred within the first 100 nucleotides of the carboxy terminal NF-KB activation domain-a critical sequence for the protein half-life-not a single point mutation was found in the remaining 62 nucleotides, necessary for malignant transformation. Such a clustering of nonrandom sequence variations, associated with a high oncoprotein expression in immunocompromised hosts, suggests that this part of the LMPl oncogene behaves as a hypervariable region with natural selection of growth-promoting variants through prolongation of the protein half-life.
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tinocytes,x inhibits human epithelial cell differentiation,' induces DNA synthesis," and upregulation of bcl-2 expression." In transgenic mice, LMPl induces hyperplastic dermatitis and abnormal keratin expression."
Recent studies indicate that LMPl may stimulate intercellular and intracellular signal transduction pathways." In particular, the membrane-spanning segments together with the carboxy terminal 55 amino acids of this oncoprotein are required for maximal stimulation of NF-KB, a transcription factor controlling the expression of genes involved in cell activation and growth c~n t r o l . '~. '~ Stimulation of NF-KB activity appears to occur through phosphorylation and degradation of the inhibitory molecule IKBCX, followed by translocation of free NF-KB to the nucleus. I6 We recently reported in this journal the identification of clustered point mutations and deletions within that region of the oncogene in clinically aggressive cases of HIV-negative HD with high LMPl expre~sion.",~~ High LMPl expression associated with bcl-2 oncoprotein expression in AIDS-related primary brain lymphomas (HIV-PBL) was just reported in the same forum." These observations prompted us to test whether clustering of nonrandom point mutations within the NF-KB activation domain of the LMPl gene was a common finding in immunocompromised hosts. Overall, 17 AIDSrelated large cell lymphomas (including 6 brain lymphomas and 7 systemic large cell lymphomas [HIV-LCL] from ref 19) and 8 HIV-, LMPl-expressing atypical lymphoproliferations have been analyzed. Our findings show that a particular variant sequence of the NF-KB activation domain of the LMPl gene is predominant in EBV-related lymphoproliferative disorders in immunocompromised hosts.
MATERIALS AND METHODS
Tissue samples, histology, and immunohistology. A survey of the origin of the 25 cases analyzed is presented in Table 1 . Diagnosis of lymphoma or lymphoproliferative disorder was performed on 4-pm tissue sections stained with hematoxilin-eosin. LMPl was de- (Fig 3) , which are identical to the first six amino acids of the carboxy terminal region of the NF-KB activation domain. Interestingly, the 69-bp deletion originates also in this region. Overall, the same mutation pattern was observed in HIV-PBL, HIV-LCL, and HIV-LPD.
In case 19 the posttransplant B-cell lymphoma occurred in a pretransplant EBV-host, indicating the donor kidney as a source of EBV infection. PCR-driven amplification of DNA extracted from donor PBMC using primers for the critical carboxy terminal region of the LMPl gene showed two bands migrating at 3 16 and 286 bp, respectively. Sequencing confirmed the presence of the deletion variant identified in the B-cell lymphoma, but showed also presence of wild-type LMPl, not identifiable in the tumor. In the 52 nonmalignant reactive conditions, carboxy terminal LMPl deletions were identified in 10 samples (19%). The presence of carboxy terminal LMPl deletions was significantly associated with malignant lymphoproliferations compared with <""""""" ; <"""""""""""""""> overall reactive conditions (P < ,001). Interestingly, in reactive conditions most LMPl deletions (6 of 17) occurred in the florid infectious mononucleosis cases.
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DISCUSSION
The results of this study indicate that the carboxy terminal NF-KB activation domain of the LMPl gene expressed in AIDS-related primary brain lymphomas and disseminated lymphomas is characterized by the presence of a high number of nonrandom point mutations including distinct 30-and 69-bp deletions. This mutational pattern was previously identified in aggressive (relapsing) HD6,I7,l8 atypical Bor T-cell lymphoproliferative disorder^,*^-^^ posttransplant lymphoma^,'^ and HIV-associated oral hairy leukoplakia.28
Our original observation of strong LMPl oncoprotein expression in such casesr7 is now confirmed in a larger series because 13 of the AIDS-related lymphomas (6 primary brain, 7 systemic) molecularly analyzed in the present report have been shown to express LMPl oncoprotein at high levels when assessed by immunostaining." The identification of numerous tumor cells with a strong staining signal for LMPl appears to us indicative of oncoprotein expression at high levels because abundant LMPl mRNA transcripts have been identified in similar condition^.'^ Interestingly, this mutational pattern is found in a setting of profound T-cell anergy, ie, central nervous system lymphoma in AIDS patients, and of diminished T-cell-mediated immunity, ie, angioimmunoblastic lymphadenopathy (AILD) and HD. The chief difference lies in the number of LMP1-expressing cells, which is very high in HIV-PBL and HIV-LCL, but small to intermediate in AILD and HD. However, when transformation of AILD into B-immunoblastic lymphoma occurs, abundant LMP1-expressing tumor cells are observed.26 This pattern is best explained by the hypothesis that the mutations within the carboxy terminal domain of LMPl confer a growth advantage to lymphoid cells, still partially counterbalanced in AILD and HD by the host's immune response. A further decrease in cell-mediated immunity may then lead to an uncontrolled immunoblastic proliferation resulting in B-immunoblastic lymphoma or lymphocyte-depleted HD. Indeed, the outgrowth of the donor-derived LMPl deletion variant but not of the donorderived LMPl wild type in the B-immunoblastic lymphoma of the initially EBV-host after renal transplantation (case 19) is consistent with a growth advantage of the LMPl deletion variant over the wild type in the immunosuppressed host.
Several recent findings are in favor of a natural selection process of LMPl deletion variants. First, all deletions and most amino acid substitutions are located within the carboxy terminal LMPl domain required for maximal NF-KB-mediated tran~cription.'~"~ Deletions and mutations are restricted to the first 33 amino acids in this region, whereas not a single substitution is observed within the remaining 22 amino acids, a region that is necessary for transformation of Rat-l fibro- <"""""""> Ser <"""""""> Ser <""""""""""""""""""""-> from prolongation of the oncoprotein half-life. This basic mechanism which favors virus growth would also explain that identical carboxy terminal LMPl-del variants are observed in both strain A and B of EBV,25,35 and that LMPldel variants are found in 30% to 35% of patients presenting with florid infectious m o n o n u c l e o~i s~~~~~ but in only 10% of EBVC controls without clinical history of this disorder.
